Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;108(2):124-31.
doi: 10.1007/s00347-010-2210-z.

[Anti-VEGF therapy of exudative AMD: Prognostic factors for therapy success]

[Article in German]
Affiliations

[Anti-VEGF therapy of exudative AMD: Prognostic factors for therapy success]

[Article in German]
B Heimes et al. Ophthalmologe. 2011 Feb.

Abstract

Background: The aim of the study was to evaluate possible prognostic and predictive factors (morphologic and functional) of the individual visual gain/decline after anti-VEGF therapy of exudative AMD.

Patients/methods: Best corrected visual acuity (VA), microperimetric sensitivity (RS), retinal thickness (RT) and autofluorescence pattern (AF) were documented in 128 patients with exudative AMD.

Results: Eyes with classic choroidal neovascularization (CNV) had the best visual gain but still remained at a lower level. Eyes which initially had the lowest VA had the largest gain and those with good initial VA could maintain this level. There was no correlation between RT and visual outcome. Eyes with initially normal AF had a significantly greater visual gain.

Conclusions: The type of CNV, initial VA, RS and the initial RT were only of limited usefulness, while the initial foveal AF was most important predictive factor. This may indicate that preexisting changes and irreversible damage in the outer retina and/or retinal pigment epithelium are responsible for the resulting VA after therapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. N Engl J Med. 2006 Oct 5;355(14):1419-31 - PubMed
    1. Graefes Arch Clin Exp Ophthalmol. 2008 Sep;246(9):1229-34 - PubMed
    1. Arch Ophthalmol. 2007 Nov;125(11):1460-9 - PubMed
    1. Am J Ophthalmol. 2007 Dec;144(6):850-857 - PubMed
    1. Am J Ophthalmol. 2008 Feb;145(2):239-248 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources